Clinical research

Treatment of de novo bifurcation lesions: comparison of Sirolimus- and Paclitaxel-eluting stents

EuroIntervention 2005;1:24-30 - DOI10.4244/EIJV1I1A01.

Angela Hoye
Angela Hoye, MB, ChB; Carlos AG van Mieghem, MD; Andrew TL Ong, MD; Jiro Aoki, MD; Gaston A. Rodriguez Granillo, MD; Marco Valgimigli, MD; Keiichi Tsuchida, MD; Georgios Sianos MD, PhD; Eugene McFadden, MB, ChB, MD, FACC; Willem J. van der Giessen, MD, PhD; Pim J. de Feyter, MD, PhD, FACC; Ron T. van Domburg, PhD; Patrick W. Serruys, MD, PhD, FACC
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands

Objective: Both the sirolimus-(SES) and paclitaxel-eluting (PES) stents have been shown to reduce restenosis rates when used in relatively simple lesions. This study aimed to evaluate the results of a consecutive

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

drug eluting stentbifurcation lesionssirolimuspaclitaxel
Read next article
Influence of technical strategies on the outcome of coronary bifurcation stenting

Latest news